Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,749
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +3.1%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,044)

clinicaltrialsPublishedShowing 51–100 of 1,009 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02438722	S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer	completed	Phase 2 / Phase 3	174	SWOG Cancer Research NetworkNETWORK	1	May 18, 2026	clinicaltrials
NCT02444741	Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer	completed	Phase 1 / Phase 2	124	M.D. Anderson Cancer CenterOTHER	1